Skip to main content
SpringerLink
Log in

High dose rate brachytherapy in the treatment of prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

The optimal treatment of patients with localized prostate cancer remains controversial. Significant clinical data are available, however, demonstrating that patients treated with radiation therapy (RT) have a significantly better outcome as the dose to the gland is increased. What remains debatable, however, is how to best deliver these higher doses of RT without significantly increasing normal tissue toxicities. Conformal high dose rate brachytherapy (C-HDR BT) represents an alternative means of precise dose delivery that offers similar tumoricidal effects as three-dimensional (3D) conformal external beam radiotherapy (EBRT) or permanent interstitial prostate seed implants with potential additional advantages. Since C-HDR BT consists of temporarily placing afterloading needles or catheters directly into the prostate gland under real-time ultrasound guidance, a steep dose gradient between the prostate and adjacent normal tissues can be generated that is minimally affected by organ motion and edema or treatment setup uncertainties. The ability to control the amount of time the single HDR radioactive source "dwells" at each position along the length of each brachytherapy catheter further enhances the conformity of the dose. In addition, recent radiobiological data on prostate cancer treatment suggest that C-HDR BT should produce tumor control and late normal tissue side effects that are at least as good as achieved with conventional fractionation, with the additional possibility that acute side effects might be reduced. Published data from several groups performing C-HDR BT as boosts in patients with locally advanced disease have supported these assumptions. Combined with the physical advantages discussed above, C-HDR BT should provide similar tumor control as 3D conformal EBRT with the added advantages of reduced treatment times, less acute toxicity, and no additional technological requirements to account and correct for treatment setup uncertainties and organ motion. Due to the success of C-HDR BT as boost treatment in locally advanced disease, this form of radiation treatment has recently been applied to low-risk prostate cancer patients as an alternative brachytherapy technique to permanent interstitial seed implantation. Advantages in this setting include an improved ability to define and deliver the prescribed dose, a significantly shortened treatment schedule compared to 3D conformal EBRT, and the fact that patients are not radioactive after implantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez TJ, Pfeffer JR, Lino CC, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106

    Article  CAS  PubMed  Google Scholar 

  2. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295–300

    Google Scholar 

  3. Borghede G, Hedelin H, Holmang S, Johansson KA, Aldenborg F, Pettersson S, Sernbo G, Wallgren A, Mercke C (1997) Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 44:237–244

    Article  CAS  PubMed  Google Scholar 

  4. Borghede G, Hedelin H, Holmang S, Johansson KA, Sernbo G, Mercke C (1997) Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland. Radiother Oncol 44:245–250

    Article  CAS  PubMed  Google Scholar 

  5. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6–13

    Article  PubMed  Google Scholar 

  6. Curran MJ, Healey GA, Bihrle W, III, Goodman N, Roth RA (2000) Treatment of high-grade low-stage prostate cancer by high-dose-rate brachytherapy. J Endourol 14:351–356

    CAS  PubMed  Google Scholar 

  7. D'Souza WD, Thames HD (2001) Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51:1–3

    Google Scholar 

  8. Deger S, Boehmer D, Turk I, Roigas J, Wernecke KD, Wiegel T, Hinkelbein W, Dinges S, Budach V, Loening SA (2002) High dose rate brachytherapy of localized prostate cancer. Eur Urol 41:420–426

    Article  PubMed  Google Scholar 

  9. Deger S, Dinges S, Roigas J, Schnorr D, Turk I, Budach V, Hinkelbein W, Loening SA (1997) High-dose rate iridium192 afterloading therapy in combination with external beam irradiation for localized prostate cancer. Tech Urol 3:190–194

    CAS  PubMed  Google Scholar 

  10. Demanes DJ, Rodriguez RR, Altieri GA (2000) High dose rate prostate brachytherapy: the California Endocurietherapy (CET) method. Radiother Oncol 57:289–296

    Article  CAS  PubMed  Google Scholar 

  11. Duchesne GM, Peters LJ (1999) What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 44:747–748

    CAS  PubMed  Google Scholar 

  12. Edmundson GK, Yan D, Martinez AA (1995) Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Int J Radiat Oncol Biol Phys 33:1257–1263

    Article  CAS  PubMed  Google Scholar 

  13. Fiveash JB, Hanks G, Roach M, Wang S, Vigneault E, McLaughlin PW, Sandler HM (2000) 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 47:335–342

    Article  CAS  PubMed  Google Scholar 

  14. Forman JD, Porter AT (1997) The experience with neutron irradiation in locally advanced adenocarcinoma of the prostate. Semin Urol Oncol 15:239–243

    CAS  PubMed  Google Scholar 

  15. Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021–1031

    Google Scholar 

  16. Fowler JF, Chappell RJ, Ritter MA (2002) The prospects for new treatments for prostate cancer. Int J Radiat Oncol Biol Phys 52:3–5

    Article  PubMed  Google Scholar 

  17. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, Strawderman MS, Grijalva KH, Kish KE, Lichter AS (1997) Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 38:311–317

    Article  CAS  PubMed  Google Scholar 

  18. Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, Bertermann H, Buschbeck B, Kohr P, Kimmig B (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90

    Article  PubMed  Google Scholar 

  19. Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, Paulson DF, Middleton AW, Jr., Rukstalis DB, Smith JA, Jr., Ohori M, Theiss M, Schellhammer PF (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32:385–390

    CAS  PubMed  Google Scholar 

  20. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555–565

    CAS  PubMed  Google Scholar 

  21. Hanks GE (2000) Conformal radiotherapy for prostate cancer. Ann Med 32:57–63

    CAS  PubMed  Google Scholar 

  22. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46:823–832

    Article  CAS  PubMed  Google Scholar 

  23. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE (1999) Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 5:152–158

    CAS  PubMed  Google Scholar 

  24. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA (1998) Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501–510

    Article  CAS  PubMed  Google Scholar 

  25. Kestin LL, Martinez AA, Stromberg JS, Edmundson GK, Gustafson GS, Brabbins DS, Chen PY, Vicini FA (2000) Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 18:2869–2880

    CAS  PubMed  Google Scholar 

  26. Kini VR, Edmundson GK, Vicini FA, Jaffray DA, Gustafson G, Martinez AA (1999) Use of three-dimensional radiation therapy planning tools and intraoperative ultrasound to evaluate high dose rate prostate brachytherapy implants. Int J Radiat Oncol Biol Phys 43:571–578

    Article  CAS  PubMed  Google Scholar 

  27. Lattanzi J, McNeeley S, Donnelly S, Palacio E, Hanlon A, Schultheiss TE, Hanks GE (2000) Ultrasound-based stereotactic guidance in prostate cancer-quantification of organ motion and set-up errors in external beam radiation therapy. Comput Aided Surg 5:289–295

    Article  CAS  PubMed  Google Scholar 

  28. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, Vicini FA (2003) Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169:974–979

    PubMed  Google Scholar 

  29. Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, Spencer W, Stromberg J, Huang R, Vicini F (2002) Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53:316–327

    Article  PubMed  Google Scholar 

  30. Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA (2000) Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. Int J Radiat Oncol Biol Phys 47:343–352

    Article  CAS  PubMed  Google Scholar 

  31. Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G (2001) Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49:61–69

    Article  CAS  PubMed  Google Scholar 

  32. Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L (1998) High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 41:525–533

    Article  CAS  PubMed  Google Scholar 

  33. Michalski JM, Purdy JA, Winter K, Roach M, III, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD (2000) Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46:391–402

    Article  CAS  PubMed  Google Scholar 

  34. Nag S, Gupta N (2000) A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 46:507–513

    Article  CAS  PubMed  Google Scholar 

  35. Oefelein MG, Smith ND, Grayhack JT, Schaeffer AJ, McVary KT (1997) Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol 158:1460–1465

    CAS  PubMed  Google Scholar 

  36. Paul R, Hofmann R, Schwarzer JU, Stepan R, Feldmann HJ, Kneschaurek P, Molls M, Hartung R (1997) Iridium 192 high-dose-rate brachytherapy—a useful alternative therapy for localized prostate cancer? World J Urol 15:252–256

    Google Scholar 

  37. Pellizzon AC, Nadalin W, Salvajoli JV, Fogaroli RC, Novaes PE, Maia MA, Ferrigno R (2003) Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 66:167–172

    Article  PubMed  Google Scholar 

  38. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013–1021

    CAS  PubMed  Google Scholar 

  39. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904–3911

    CAS  PubMed  Google Scholar 

  40. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105

    Article  PubMed  Google Scholar 

  41. Ragde H, Elgamal AA, Snow PB, Brandt J, Bartolucci AA, Nadir BS, Korb LJ (1998) Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma [see comments]. Cancer 83:989–1001

    Article  PubMed  Google Scholar 

  42. Stromberg JS, Martinez AA, Horwitz EM, Gustafson GS, Gonzalez JA, Spencer WF, Brabbins DS, Dmuchowski CF, Hollander JB, Vicini FA (1997) Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment. Cancer J Sci Am 3:346–352

    CAS  PubMed  Google Scholar 

  43. Syed AM, Puthawala A, Sharma A, Gamie S, Londrc A, Cherlow JM, Damore SJ, Nazmy N, Sheikh KM, Ko SJ (2001) High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. Cancer Control 8:511–521

    CAS  PubMed  Google Scholar 

  44. Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA (2001) Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better? Int J Radiat Oncol Biol Phys 51:1200–1208

    Google Scholar 

  45. Vicini FA, Kestin LL, Martinez AA (2000) Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Tech Urol 6:135–145

    CAS  PubMed  Google Scholar 

  46. Yan D, Lockman D (2001) Organ/patient geometric variation in external beam radiotherapy and its effects. Med Phys 28:593–602

    Article  CAS  PubMed  Google Scholar 

  47. Yan D, Xu B, Lockman D, Kota K, Brabbins DS, Wong J, Martinez AA (2001) The influence of interpatient and intrapatient rectum variation on external beam treatment of prostate cancer. Int J Radiat Oncol Biol Phys 51:1111–1119

    Article  CAS  PubMed  Google Scholar 

  48. Yoshioka Y, Nose T, Yoshida K, Inoue T, Yamazaki H, Tanaka E, Shiomi H, Imai A, Nakamura S, Shimamoto S, Inoue T (2000) High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 48:675–681

    Article  CAS  PubMed  Google Scholar 

  49. Yoshioka Y, Nose T, Yoshida K, Oh RJ, Yamada Y, Tanaka E, Yamazaki H, Inoue T, Inoue T (2003) High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56:213–220

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, William Beaumont Hospital, 3601 W. 13 Mile Rd, Royal Oak, MI 48072, USA

    Frank Vicini, Carlos Vargas, Gary Gustafson, Gregory Edmundson & Alvaro Martinez

Authors
  1. Frank Vicini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Vargas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary Gustafson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory Edmundson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alvaro Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Vicini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vicini, F., Vargas, C., Gustafson, G. et al. High dose rate brachytherapy in the treatment of prostate cancer. World J Urol 21, 220–228 (2003). https://doi.org/10.1007/s00345-003-0358-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-003-0358-8

Keywords

Search

Navigation